Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function-Reference-Cited by-同舟云学术

Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function

Published:2015-10-29 Issue:1 Volume:5 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Barucker Christian,Bittner Heiko J.,Chang Philip K.-Y.,Cameron Scott,Hancock Mark A.,Liebsch Filip,Hossain Shireen,Harmeier Anja,Shaw Hunter,Charron François M.,Gensler Manuel,Dembny Paul,Zhuang Wei,Schmitz Dietmar,Rabe Jürgen P.,Rao Yong,Lurz Rudi,Hildebrand Peter W.,McKinney R. Anne,Multhaup Gerhard

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep15410.pdf

Reference76 articles.

1. Younkin, S. G. The role of A beta 42 in Alzheimer’s disease. J Physiol Paris 92, 289–92 (1998).

2. Gong, Y. et al. Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100, 10417–22 (2003).

3. Shankar, G. M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 2866–75 (2007).

4. Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15, 349–57 (2012).

5. Morley, J. E. et al. A physiological role for amyloid-beta protein:enhancement of learning and memory. J Alzheimers Dis 19, 441–9 (2010).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer's disease pathophysiology in the Retina;Progress in Retinal and Eye Research;2024-07

2. Ameliorating Effects of Aloe Emodin in an Aluminum‐Induced Alzheimer’s Disease Rat Model;Journal of Food Biochemistry;2024-01

3. Novel Strategy for Alzheimer’s Disease Treatment through Oral Vaccine Therapy with Amyloid Beta;Biologics;2023-02-01

4. Mixed pathology as a rule, not exception: Time to reconsider disease nosology;Precision Medicine in Neurodegenerative Disorders, Part I;2023

5. Biophysical characterization as a tool to predict amyloidogenic and toxic properties of amyloid‐β42 peptides;FEBS Letters;2022-05-10